Bicara Therapeutics Inc. Common Stock (BCAX) Research
Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara Therapeutics operates as a subsidiary of Biocon Limited.
Market snapshot
- Symbol
- BCAX
- Price
- $23.23
- Day change
- +1.35%
- Market cap
- $1.3B
- P/E ratio
- -8.97x
- 52-week range
- 8.48-24.25
- Sector
- Healthcare
- Industry
- Biotechnology
- Next earnings
- in 2 months
- Analyst price target
- $31.25
Recent news
- Bicara gains buy rating as BofA sees SoC potential in cancer drug Ficera
Bank of America has initiated coverage of Bicara Therapeutics (NASDAQ:BCAX) with a “Buy” rating and a $35 price objective, citing the potential of its lead drug candidate to reshape first-line treatment for a form of head and neck cancer, according to a research note published Tuesday. The analysts pointed to the company's lead asset ficerafusp alfa (ficera) as the central driver of their outlook.
Peer companies
Recent insider activity
- RA CAPITAL MANAGEMENT, L.P. — A-Award (19475 shares) on 2026-06-09
- Bowden Christopher — A-Award (19475 shares) on 2026-06-09
- Haviland Kate — A-Award (19475 shares) on 2026-06-09
- Mazumdar-Shaw Kiran — A-Award (19475 shares) on 2026-06-09
- Robertson Scott M. — A-Award (19475 shares) on 2026-06-09
Open Bicara Therapeutics Inc. Common Stock (BCAX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.